Atea’s hep C pill looks solid in phase III head-to-head HCV study

Source Summary

News of the first-ever successful head-to-head phase III study testing an oral antiviral therapy for hepatitis C virus (HCV) might not have had much impact on Atea Pharmaceuticals Inc.’s share price, but analysts remained optimistic for the future of the once-daily fixed-dose combination of bemnifosbuvir and ruzasvir.